Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (57795) 57795
Book Review (7086) 7086
Newsletter (5442) 5442
Publication (2299) 2299
Book Chapter (228) 228
Conference Proceeding (225) 225
Magazine Article (158) 158
Dissertation (110) 110
Newspaper Article (60) 60
Trade Publication Article (21) 21
Book / eBook (11) 11
Web Resource (9) 9
Government Document (4) 4
Data Set (3) 3
Paper (2) 2
Journal / eJournal (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (46368) 46368
humans (35237) 35237
cyclosporine (27560) 27560
male (22664) 22664
female (18572) 18572
transplantation (16110) 16110
animals (15703) 15703
adult (13806) 13806
cyclosporine - therapeutic use (12340) 12340
middle aged (12149) 12149
immunosuppressive agents - therapeutic use (11383) 11383
surgery (10666) 10666
cyclosporine-a (10632) 10632
immunology (10422) 10422
cyclosporine - pharmacology (8080) 8080
rats (7732) 7732
pharmacology & pharmacy (6556) 6556
cyclosporine - administration & dosage (5646) 5646
adolescent (5376) 5376
treatment outcome (5345) 5345
aged (5171) 5171
time factors (5139) 5139
tacrolimus (5066) 5066
cyclosporine - adverse effects (5062) 5062
immunosuppressive agents - adverse effects (4945) 4945
kidney transplantation (4607) 4607
immunosuppressive agents - administration & dosage (4587) 4587
immunosuppression (4576) 4576
research (4421) 4421
drug therapy, combination (4411) 4411
mice (4410) 4410
child (4341) 4341
therapy (4190) 4190
immunosuppressive agents - pharmacology (4104) 4104
recipients (4089) 4089
retrospective studies (3973) 3973
drugs (3908) 3908
urology & nephrology (3583) 3583
follow-up studies (3534) 3534
kidney transplantation - immunology (3460) 3460
abridged index medicus (3454) 3454
biochemistry & molecular biology (3326) 3326
graft rejection - prevention & control (3115) 3115
tacrolimus - therapeutic use (3011) 3011
analysis (2970) 2970
risk factors (2953) 2953
dose-response relationship, drug (2940) 2940
hematology (2881) 2881
transplantation, homologous (2861) 2861
expression (2785) 2785
cyclosporin a (2761) 2761
cyclosporine a (2670) 2670
pharmacokinetics (2663) 2663
kidneys (2622) 2622
child, preschool (2516) 2516
oncology (2475) 2475
transplantation of organs, tissues, etc (2448) 2448
cells, cultured (2337) 2337
calcineurin inhibitors (2331) 2331
cyclosporine - pharmacokinetics (2278) 2278
immunosuppressive agents - pharmacokinetics (2221) 2221
mycophenolic acid - analogs & derivatives (2197) 2197
medical research (2155) 2155
apoptosis (2142) 2142
cyclosporine - blood (2139) 2139
disease (2135) 2135
rejection (2130) 2130
cells (2029) 2029
graft survival (2029) 2029
rats, sprague-dawley (2013) 2013
dermatology (2010) 2010
care and treatment (2004) 2004
cell biology (2000) 2000
fk506 (1992) 1992
prospective studies (1962) 1962
health aspects (1930) 1930
children (1925) 1925
universities and colleges (1911) 1911
tacrolimus - pharmacology (1902) 1902
azathioprine - therapeutic use (1895) 1895
medicine, experimental (1894) 1894
kidney transplantation - physiology (1877) 1877
sirolimus (1842) 1842
calcineurin (1840) 1840
pediatrics (1831) 1831
medicine, general & internal (1804) 1804
immunosuppressive agents (1791) 1791
rats, wistar (1780) 1780
mycophenolate-mofetil (1762) 1762
reports (1757) 1757
drug interactions (1748) 1748
gastroenterology & hepatology (1745) 1745
administration, oral (1744) 1744
inhibition (1740) 1740
renal-transplantation (1716) 1716
p-glycoprotein (1670) 1670
mycophenolic acid - therapeutic use (1653) 1653
creatinine - blood (1648) 1648
nephrotoxicity (1631) 1631
immunosuppressive agents - blood (1617) 1617
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (59332) 59332
German (941) 941
French (919) 919
Spanish (598) 598
Japanese (504) 504
Chinese (397) 397
Korean (265) 265
Italian (186) 186
Russian (165) 165
Polish (151) 151
Portuguese (148) 148
Czech (60) 60
Turkish (47) 47
Hungarian (35) 35
Dutch (25) 25
Danish (15) 15
Croatian (14) 14
Finnish (13) 13
Serbian (13) 13
Ukrainian (13) 13
Norwegian (10) 10
Romanian (9) 9
Slovak (9) 9
Persian (7) 7
Hebrew (5) 5
Lithuanian (3) 3
Swedish (3) 3
Afrikaans (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Screening assessment - cyclosporin A and cyclosporin E
: Chemical Abstracts Service registry numbers 59865-13-3 and 63798-73-2
and Canada. Environment Canada, issuing bodyCanada. Health Canada, issuing body
2015, ISBN 110025658X
Toxicology | Cyclosporine
Web Resource
Details down arrow
2. Full Text Time-lapse imaging of Ca.sup.2+-induced swelling and permeability transition: Single mitochondrion study
by Shibata, Takahiro and Yoneda, Mayu and Morikawa, Daisuke and Ohta, Yoshihiro
Archives of Biochemistry and Biophysics, ISSN 0003-9861, 03/2019, Volume 663, p. 288
Mitochondrial functions are closely related to the membrane structure. Mitochondrial swelling, which is accompanied with dissipation of the crista structure... 
Permeability | Cyclosporine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Calcineurin inhibitors: 40 Years later, can't live without
by Azzi, Jamil R and Sayegh, Mohamed H and Mallat, Samir G
Journal of Immunology, ISSN 0022-1767, 12/2013, Volume 191, Issue 12, pp. 5785 - 5791
Calcineurin inhibitors (CNIs) revolutionized the field of organ transplantation and remain the standard of care 40 years after the discovery of cyclosporine.... 
COSTIMULATION BLOCKADE | ANTILYMPHOCYTIC AGENT | RHEUMATOID-ARTHRITIS | CYCLOSPORINE-A | GLOMERULAR-DISEASES | REGULATORY T-CELLS | RANDOMIZED-TRIAL | MEMBRANOUS NEPHROPATHY | GRAFT-SURVIVAL | IMMUNOLOGY | RENAL-TRANSPLANT RECIPIENTS | Meta-Analysis as Topic | History, 21st Century | Cyclosporine - pharmacology | Humans | Immunosuppressive Agents - therapeutic use | Tacrolimus - history | Calcineurin Inhibitors | Multicenter Studies as Topic | Immunosuppressive Agents - history | T-Lymphocytes - drug effects | Kidney Diseases - chemically induced | Tacrolimus - pharmacology | Drug Evaluation, Preclinical | Drug Therapy, Combination | Immunosuppressive Agents - pharmacology | Autoimmune Diseases - drug therapy | Cyclosporine - history | Kidney Transplantation - history | Graft Rejection - prevention & control | History, 20th Century | Tacrolimus - chemistry | Kidney Diseases - drug therapy | Clinical Trials as Topic | Tacrolimus - adverse effects | Forecasting | Randomized Controlled Trials as Topic | Calcineurin - physiology | Kidney Diseases - immunology | Cyclosporine - therapeutic use | Tacrolimus - therapeutic use | Animals | Cyclosporine - chemistry | Lymphocyte Activation - drug effects | Cyclosporine - adverse effects | Immunosuppressive Agents - adverse effects | T-Lymphocytes - immunology | Diabetes Mellitus, Type 2 - chemically induced | Immunosuppressive Agents - chemistry | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Topical delivery of Cyclosporine A into the skin using SPACE-peptide
by Chen, Ming and Kumar, Sunny and Anselmo, Aaron C and Gupta, Vivek and Slee, Deborah H and Muraski, John A and Mitragotri, Samir
Journal of Controlled Release, ISSN 0168-3659, 02/2015, Volume 199, pp. 190 - 197
Cyclosporine A (CsA) is used for the treatment of psoriasis; however systemic administration of CsA is potentially life threatening and there are long-term... 
Cyclosporine A | Skin penetrating peptide | Topical delivery | Biodistribution | Skin penetrating peptide Cyclosporine A Topical delivery Biodistribution | PERCUTANEOUS PENETRATION | ORAL CYCLOSPORINE | TRANSDERMAL DELIVERY | CHEMISTRY, MULTIDISCIPLINARY | ALOPECIA-AREATA | ATOPIC-DERMATITIS | IN-VITRO | ENHANCEMENT | LOW-DOSE CYCLOSPORINE | PHARMACOLOGY & PHARMACY | INTRALESIONAL CYCLOSPORINE | PSORIASIS | Solvents | Excipients | Ethanol | Mice, Hairless | Chemistry, Pharmaceutical | Drug Carriers | Drug Delivery Systems | Tissue Distribution | Cell-Penetrating Peptides - pharmacology | Animals | Solutions | Swine | Cyclosporine - administration & dosage | Cyclosporine - pharmacokinetics | Skin Absorption - drug effects | Mice | In Vitro Techniques | Administration, Topical | Skin | Permeability | Peptides | Psoriasis | Transdermal medication | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Role of cyclosporine in the occurrence of neuro-Behcet's disease?
by Martin, M and Gil, H and Hafsaoui, C and Meaux-Ruault, N and Magy-Bertrand, N
La Revue de medecine interne, ISSN 0248-8663, 11/2010, Volume 31, Issue 11, p. e7-e8
Une atteinte neurologique centrale survient chez 10 a 20 % des malades ayant une maladie de Behcet (neuro-Behcet). Nous rapportons une nouvelle observation... 
Cyclosporine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Effect of Cyclosporine on Reperfusion Injury in Acute Myocardial Infarction
by Piot, Christophe and Croisille, Pierre and Staat, Patrick and Thibault, Hélène and Rioufol, Gilles and Mewton, Nathan and Elbelghiti, Rachid and Cung, Thien Tri and Bonnefoy, Eric and Angoulvant, Denis and Macia, Christophe and Raczka, Franck and Sportouch, Catherine and Gahide, Gerald and Finet, Gérard and André-Fouët, Xavier and Revel, Didier and Kirkorian, Gilbert and Monassier, Jean-Pierre and Derumeaux, Geneviève and Ovize, Michel
The New England Journal of Medicine, ISSN 0028-4793, 07/2008, Volume 359, Issue 5, pp. 473 - 481
Experimental evidence suggests that cyclosporine may attenuate myocardial reperfusion injury. In a pilot trial, 58 patients with acute ST-elevation myocardial... 
HOSPITAL DISCHARGE | HEART | APOPTOSIS | MEDICINE, GENERAL & INTERNAL | MITOCHONDRIAL PERMEABILITY TRANSITION | CYCLOPHILIN-D | MYOCYTES | PORE | SIZE | ISCHEMIA | CELL-DEATH | Single-Blind Method | Creatine Kinase - blood | Mitochondrial Membrane Transport Proteins - antagonists & inhibitors | Area Under Curve | Humans | Middle Aged | Male | Combined Modality Therapy | Biomarkers - blood | Troponin I - blood | Cyclosporine - blood | Angioplasty, Balloon, Coronary - adverse effects | Cyclosporine - therapeutic use | Magnetic Resonance Imaging | Myocardial Infarction - therapy | Pilot Projects | Myocardial Infarction - drug therapy | Cyclosporine - adverse effects | Myocardial Infarction - pathology | Female | Myocardial Reperfusion Injury - prevention & control | Premedication | Evaluation | Dosage and administration | Cyclosporine | Drug therapy | Heart attack | Heart attacks | Medical imaging | Permeability | Ischemia | Cardiology | Veins & arteries | Index Medicus | Abridged Index Medicus | Life Sciences | Other
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Self-micellizing solid dispersion of cyclosporine A with improved dissolution and oral bioavailability
by Onoue, Satomi and Suzuki, Hiroki and Kojo, Yoshiki and Matsunaga, Saori and Sato, Hideyuki and Mizumoto, Takahiro and Yuminoki, Kayo and Hashimoto, Naofumi and Yamada, Shizuo
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 10/2014, Volume 62, pp. 16 - 22
The present study aimed to develop a self-micellizing solid dispersion (SMSD) of cyclosporine A (CsA) using an amphiphilic block copolymer, poly[MPC- -BMA], to... 
Cyclosporine A | Self-micellization | Solid dispersion | Stability | Dissolution | BEHAVIOR | DELIVERY-SYSTEMS | DOSAGE FORMS | FORMULATION | IN-VITRO | PHARMACOKINETICS | WATER-SOLUBLE DRUGS | CLASSIFICATION-SYSTEM | PHARMACOLOGY & PHARMACY | ABSORPTION | COPOLYMER | Cell Line | Cell Survival - drug effects | Drug Stability | Immunosuppressive Agents - pharmacokinetics | Solubility | Biological Availability | Male | Methacrylates - chemistry | Phosphorylcholine - analogs & derivatives | Rats, Sprague-Dawley | Chemistry, Pharmaceutical | Cyclosporine - blood | Animals | Immunosuppressive Agents - blood | Cyclosporine - chemistry | Micelles | Cyclosporine - administration & dosage | Cyclosporine - pharmacokinetics | Phosphorylcholine - chemistry | Immunosuppressive Agents - administration & dosage | Immunosuppressive Agents - chemistry | Cyclosporine | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Supercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: Comparative study with the conventional cyclosporin A emulsion
by Karn, Pankaj Ranjan and Do Kim, Hyun and Kang, Han and Sun, Bo Kyung and Jin, Su-Eon and Hwang, Sung-Joo
International Journal of Nanomedicine, ISSN 1176-9114, 08/2014, Volume 9, Issue 1, pp. 3791 - 3800
Background: The objective of this study was to compare the efficacy of cyclosporin (CsA)-encapsulated liposomes with the commercially available CsA emulsion... 
Dry eye syndrome | Supercritical fluid | Cyclosporin A | Liposomes | EFFICACY | liposomes | DRUG-DELIVERY | STABILITY | cyclosporin A | NANOSCIENCE & NANOTECHNOLOGY | FORMULATION | IN-VITRO | dry eye syndrome | TOPICAL CYCLOSPORINE | OCULAR DELIVERY | BOUND CYCLOSPORINE | SYSTEMS | PHARMACOLOGY & PHARMACY | supercritical fluid | Rabbits | Liposomes - therapeutic use | Dry Eye Syndromes - drug therapy | Tears - chemistry | Male | Permeability | Cyclosporine - therapeutic use | Liposomes - chemistry | Animals | Cyclosporine - chemistry | Models, Biological | Cyclosporine - pharmacokinetics | Cyclosporine - analysis | Blinking | Disease Models, Animal | Complications and side effects | Dry eye syndromes | Physiological aspects | Dosage and administration | Cyclosporine | Research | Drug therapy | Studies | Thin films | Scanning electron microscopy | Drug delivery systems | Cornea | Particle size | Lactose | Inventors | Carbon dioxide | Alcohol | Molecular weight | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Development and characterization of mucoadhesive chitosan films for ophthalmic delivery of cyclosporine A
by Hermans, Kris and Van den Plas, Dave and Kerimova, Sabina and Carleer, Robert and Adriaensens, Peter and Weyenberg, Wim and Ludwig, Annick
International Journal of Pharmaceutics, ISSN 0378-5173, 09/2014, Volume 472, Issue 1-2, pp. 10 - 19
Ocular chitosan films were prepared in order to prolong ocular delivery of cyclosporine A. The mucoadhesive films were prepared using the solvent casting... 
Cyclosporine A | Chitosan | Films | Ocular | OCULAR INSERTS | EYE | GLYCEROL | CYCLODEXTRIN | SURFACE | PHARMACOLOGY & PHARMACY | DRUG-RELEASE | CLAY | 2-Hydroxypropyl-beta-cyclodextrin | Interleukin-2 - metabolism | Administration, Ophthalmic | Cell Line | Cell Survival - drug effects | Adhesiveness | Humans | Chitosan - administration & dosage | Plasticizers - chemistry | Drug Delivery Systems | Chitosan - chemistry | beta-Cyclodextrins - chemistry | Excipients - chemistry | Cyclosporine - chemistry | Mucous Membrane - chemistry | Cyclosporine - administration & dosage | Water - chemistry | Glycerol - chemistry | Digital integrated circuits | Cyclosporine | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs
by Agarwal, Priyanka and Scherer, Dieter and Günther, Bernhard and Rupenthal, Ilva D
International Journal of Pharmaceutics, ISSN 0378-5173, 03/2018, Volume 538, Issue 1-2, pp. 119 - 129
Semifluorinated alkanes (SFAs) are amphiphilic liquids that can dissolve hydrophobic drugs to form clear solutions. This study evaluated the potential of two... 
Cyclosporine A | Semifluorinated alkanes | Precorneal residence time | Corneal penetration | Ex vivo tissue models | PERMEABILITY | OCULAR IRRITATION | OPHTHALMIC EMULSION | DELIVERY | IN-VITRO | CYCLOSPORINE-A | HUMAN-SKIN | SILICONE OIL | PHARMACOLOGY & PHARMACY | ABSORPTION | DRY EYE DISEASE | Fluorocarbons - chemistry | Emulsions | Area Under Curve | Immunosuppressive Agents - pharmacokinetics | Solubility | Biological Availability | Drug Carriers - chemistry | Drug Delivery Systems | Cornea - metabolism | Animals | Cyclosporine - chemistry | Swine | Cyclosporine - administration & dosage | Cyclosporine - pharmacokinetics | Epithelium, Corneal - metabolism | Hydrophobic and Hydrophilic Interactions | Ophthalmic Solutions | Alkanes - chemistry | Immunosuppressive Agents - administration & dosage | Immunosuppressive Agents - chemistry | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial
by Budde, Klemens, Prof and Becker, Thomas, Prof and Arns, Wolfgang, MD and Sommerer, Claudia, MD and Reinke, Petra, Prof and Eisenberger, Ute, MD and Kramer, Stefan, PhD and Fischer, Wolfgang, PhD and Gschaidmeier, Harald, PhD and Pietruck, Frank, MD and ZEUS Study Investigators
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9768, pp. 837 - 847
Summary Background Non-nephrotoxic immunosuppressive strategies that allow reduction of calcineurin-inhibitor exposure without compromising safety or efficacy... 
Internal Medicine | SERUM CREATININE | GLOMERULAR-FILTRATION-RATE | MEDICINE, GENERAL & INTERNAL | PRIMARY IMMUNOSUPPRESSION | RENAL-ALLOGRAFT RECIPIENTS | EFFICACY | SAFETY | REDUCED-EXPOSURE CYCLOSPORINE | TACROLIMUS | MYCOPHENOLATE-MOFETIL | SIROLIMUS | Humans | Immunosuppressive Agents - pharmacokinetics | Middle Aged | Male | TOR Serine-Threonine Kinases - antagonists & inhibitors | Young Adult | Calcineurin Inhibitors | Kidney Transplantation - physiology | Cyclosporine - pharmacokinetics | Adult | Female | Mycophenolic Acid - administration & dosage | Everolimus | Immunosuppressive Agents - administration & dosage | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Glomerular Filtration Rate | Kidney Failure, Chronic - surgery | Administration, Oral | Sirolimus - pharmacokinetics | Sirolimus - administration & dosage | Cyclosporine - adverse effects | Adolescent | Cyclosporine - administration & dosage | Graft Rejection | Immunosuppressive Agents - adverse effects | Aged | Kidney Transplantation - immunology | Practice | Immunosuppression | Usage | Transplantation | Kidneys | Research | Studies | Postoperative period | Clinical medicine | Transplants & implants | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Self-micellizing solid dispersion of cyclosporine A for pulmonary delivery: Physicochemical, pharmacokinetic and safety assessments
by Suzuki, Hiroki and Ueno, Kodai and Mizumoto, Takahiro and Seto, Yoshiki and Sato, Hideyuki and Onoue, Satomi
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 01/2017, Volume 96, pp. 107 - 114
The present study aimed to develop an inhalable self-micellizing solid dispersion of cyclosporine A (SMSD/CsA) for the direct delivery to the respiratory... 
Cyclosporine A | Respirable powder | Self-micellizing solid dispersion | Dissolution | Systemic side effect | LUNG | RATS | ASTHMA | PHARMACOLOGY & PHARMACY | AIRWAYS | NEPHROTOXICITY | Allergens | Blood Urea Nitrogen | Cell Count | Immunosuppressive Agents - pharmacokinetics | Male | Drug Delivery Systems | Cyclosporine - blood | Tissue Distribution | Kidney - metabolism | Immunosuppressive Agents - blood | Micelles | Cyclosporine - pharmacokinetics | Bronchoalveolar Lavage Fluid - cytology | Lung - metabolism | Immunosuppressive Agents - administration & dosage | Ovalbumin | Lung - pathology | Microscopy, Electron, Scanning | Liver - metabolism | Solubility | Administration, Inhalation | Rats, Sprague-Dawley | Bilirubin - blood | Animals | Cyclosporine - chemistry | Lung - drug effects | Cyclosporine - administration & dosage | Creatinine - blood | Bronchoalveolar Lavage Fluid - chemistry | Immunosuppressive Agents - chemistry | Peroxidase - metabolism | Analysis | Safety and security measures | Cyclosporine | Phosphates | Urea | Methylcellulose | Lactose | Powders | Liver | Albumin | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Controlled release of cyclosporine A self-nanoemulsifying systems from osmotic pump tablets: Near zero-order release and pharmacokinetics in dogs
by Zhang, Xi and Yi, Yueneng and Qi, Jianping and Lu, Yi and Tian, Zhiqiang and Xie, Yunchang and Yuan, Hailong and Wu, Wei
International Journal of Pharmaceutics, ISSN 0378-5173, 08/2013, Volume 452, Issue 1-2, pp. 233 - 240
It is very important to enhance the absorption simultaneously while designing controlled release delivery systems for poorly water-soluble and poorly permeable... 
Cyclosporine A | Drug delivery | Osmotic tablet | Self-nanoemulsifying | Controlled release | ENHANCED ORAL BIOAVAILABILITY | CLINICAL EFFICACY | FORMULATION | IN-VITRO | TOLERABILITY | PHARMACOLOGY & PHARMACY | OPTIMIZATION | MICROENCAPSULATION | MICROEMULSION | DRUG-DELIVERY SYSTEMS | BLOOD | Osmotic Pressure | Emulsions | Tablets | Immunosuppressive Agents - pharmacokinetics | Delayed-Action Preparations - chemistry | Delayed-Action Preparations - administration & dosage | Drug Delivery Systems | Animals | Excipients - chemistry | Cyclosporine - chemistry | Cyclosporine - administration & dosage | Delayed-Action Preparations - pharmacokinetics | Dogs | Cyclosporine - pharmacokinetics | Nanostructures - chemistry | Immunosuppressive Agents - administration & dosage | Immunosuppressive Agents - chemistry | Drugs | Drug delivery systems | Cyclosporine | Vehicles | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
by Lunde, Ingrid and Bremer, Sara and Midtvedt, Karsten and Mohebi, Beata and Dahl, Miriam and Bergan, Stein and Åsberg, Anders and Christensen, Hege
European Journal of Clinical Pharmacology, ISSN 0031-6970, 6/2014, Volume 70, Issue 6, pp. 685 - 693
Tacrolimus (Tac) and cyclosporine (CsA) are mainly metabolized by CYP3A4 and CYP3A5. Several studies have demonstrated an association between the CYP3A5... 
CYP3A | POR | Biomedicine | Calcineurin inhibitors | Kidney recipients | Pharmacology/Toxicology | Pharmacokinetics | PPARA | CYP3A4-ASTERISK-22 | GENOTYPE | POLYMORPHISM | CLINICAL PHARMACOKINETICS | DOSE REQUIREMENTS | CYTOCHROME-P450 OXIDOREDUCTASE | IN-VITRO | P450 OXIDOREDUCTASE | IMPACT | PHARMACOLOGY & PHARMACY | MIDAZOLAM | NADPH-Ferrihemoprotein Reductase - genetics | Humans | Immunosuppressive Agents - pharmacokinetics | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Cyclosporine - blood | Dose-Response Relationship, Drug | Young Adult | Immunosuppressive Agents - blood | Cytochrome P-450 CYP3A - genetics | Cyclosporine - pharmacokinetics | Adult | Female | Retrospective Studies | Real-Time Polymerase Chain Reaction | Immunosuppressive Agents - administration & dosage | Tacrolimus - administration & dosage | Tacrolimus - blood | Gene Frequency | Genotype | PPAR alpha - genetics | Kidney Transplantation | Tacrolimus - pharmacokinetics | Cyclosporine - therapeutic use | Tacrolimus - therapeutic use | Analysis of Variance | Polymorphism, Restriction Fragment Length | Cyclosporine - administration & dosage | Aged | Kidneys | Tacrolimus | Cytochrome P-450 | Genetic research | Physiological aspects | Drugstores | Organ transplant recipients | Transplantation | Cyclosporine | Genetics | Pharmacology | Transplants & implants | Index Medicus | Pharmacogenetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights